199TiP A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES)

Saved in:
Bibliographic Details
Published in:Immuno-oncology technology 2022-12, Vol.16, p.100348, Article 100348
Main Authors: Gonçalves, A., Vicier, C., Guerin, M., Pignon, J., Chanez, B., Provansal Gross, M., Penel, N., Kotecki, N., Marie, D.B., Boyer Chammard, A., Paturel, C.L., André, P., Pakradouni, J., Boher, J.M., Awada, F.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2022.100348